Architect i2000sr diagnostic system

Clinical data were acquired at the time of study entry, including age, gender, cardiovascular risk factors, medication, comorbidity, blood chemistry, and hemodialysis data (dialysis duration, frequency, and access). The pre-dialysis hs-cTnT and hs-cTnI levels were measured in all subjects (single measurement). Several studies have revealed that cardiovascular events are more frequently after a long interdialytic interval than after a short interdialytic interval during hemodialysis sessions^{14 (link),15 (link)}. Therefore, we chose to obtain the blood sample of pre-dialysis hs-cTnT and hs-cTnI levels during the long dialytic period. The hs-cTnT was analyzed by electroluminescence immunoassay using Cobas e801 (Roche Diagnostics) and hs-cTnI with the ARCHITECT i2000SR Diagnostic System (Abbott). The limit of detection was 3 ng/L for hs-cTnT and 3.2 ng/L for hs-cTnI, and the coefficients of variation below 10% were 13 ng/L and 4.7 ng/L for hs-cTnT and hs-cTnI. The cutoff at the 99th percentile was 14 ng/L for hs-cTnT and 26.2 ng/L for hs-cTnI.

Troponin I level in plasma was measured using chemiluminescent microparticle immunoassay (the Abbott/Architect stat high sensitivity Troponin I assay ARCHITECT i2000SR Diagnostic System) according to the manufacturer’s instruction (Abbott Laboratories, Lake Forest, IL, USA).
N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was also determined in plasma using electrochemiluminescence immunoassay (Roche NT-proBNP assay) according to the manufacturer’s instruction (Roche Diagnostics, Basel, Switzerland).